CDC director files to sell her entire Butterfly (BFLY) stake one day after the 22% pop
Erica Schwartz's Form 144 covers all 401,699 shares she reported owning, marked at $10, the morning after Needham's initiation sent the stock up 22%. The CEO's sales were automatic or pre-scheduled, and he still holds 7.35 million shares.
Vincent Jiang · 3 min read
The director who left for the CDC is selling everything on record
Erica Schwartz stepped off Butterfly Network's board on 5 August 2026, the day the Senate confirmed her to run the CDC 45. On 22 September, the day a Buy initiation sent the stock up 21.99% to $9.93 310, she sold 78,679 Class A shares for $786,790 1. The next morning her Form 144 reached EDGAR: 323,020 more shares, aggregate market value $3,230,200 1.
Her most recent ownership filing, from 22 June, reported 401,699 shares 9. The completed sale plus the pending block equals that position exactly. Rule 144 asks no reason, and none is given 1.
The bull case is 2030 money with nothing shipped
Needham's David Saxon opened at Buy with a $10 target, a sum-of-the-parts at roughly 16 times the firm's 2027 sales estimate 3. The model carries an estimated $300 million of Midjourney licensing revenue at 2030 and about $25 million from Mendaera, and concedes no Embedded partnership has launched a commercial product; roughly two-thirds of sales are still the legacy probe business 3. Sixteen times sales across 244.9 million shares implies about $150 million of 2027 revenue, a third more than the trailing four quarters delivered 111.
Affiliates put 685,000 shares on the tape
President, CEO and chairman Joseph DeVivo disclosed $2.07 million of July and August sales, then filed a fresh 2,811-share notice the afternoon of the pop 2. Counting Schwartz's 401,699 shares, disclosed affiliate supply since July runs to about 685,000 shares, 0.28 percent of the 244,858,246 outstanding 12. Small against the float. The signal is who sold, and when.
Butterfly insider blocks grew into the pop, and the biggest is still pending
- Gross proceeds ($M)
- Estimate
Data
| Gross proceeds ($M) | |
|---|---|
| DeVivo, 20 Jul | $1.39M |
| DeVivo, 10 Aug | $0.68M |
| Schwartz, 22 Sep | $0.79M |
| Schwartz, 23 Sep (planned) (estimate) | $3.23M |
The biggest block is the one still pending
Schwartz's 22 September sale printed near $9.99 a share, within half a percent of the $10.05 52-week high 110. The pending block is marked at exactly $10. Her notice lists five vesting tranches running back to June 2024 and no Rule 10b5-1 plan date; DeVivo's carries one, adopted 12 December 2025 12. The bull case is priced in 2030 dollars; the insider paper cleared at $10.
The counter-read: the CEO is staying
DeVivo's July sale of 211,798 shares at an average $6.56 was a sell-to-cover for RSU taxes, automatic and not at his discretion, his Form 4 states 7. The August block ran under the December plan, adopted long before the run 8. He still held 7,353,700 shares after gifting 250,000 to trusts for his children, about $69 million at Wednesday's $9.42 close 63. Buyers met the tape too: 33 hedge funds held $425 million of the stock at the end of June, up from $171 million a quarter earlier 10.
What settles it
Earnings are due around 30 October, guided to $26 to $30 million of revenue and adjusted EBITDA between negative $9 million and negative $6 million 10. Butterfly has lost money in each of the last eight quarters while cash fell to $124.7 million at midyear 11. The tells are the first commercial Embedded shipment, and the Form 4 that follows her last 323,020 shares out the door.
Revenue is growing, but Butterfly has lost money for ten straight quarters
- Revenue ($M)
- Net income ($M)
Data
| Revenue ($M) | Net income ($M) | |
|---|---|---|
| Q1 '24 | $17.66M | -$21.76M |
| Q2 '24 | $21.49M | -$15.71M |
| Q3 '24 | $20.56M | -$16.92M |
| Q4 '24 | $22.35M | -$18.1M |
| Q1 '25 | $21.23M | -$13.97M |
| Q2 '25 | $23.38M | -$13.83M |
| Q3 '25 | $21.49M | -$33.97M |
| Q4 '25 | $31.51M | -$15.29M |
| Q1 '26 | $26.53M | -$12.68M |
| Q2 '26 | $32.61M | -$12.91M |
How this brief was made
01Gathered & sourced230 channels · 1,223 articles▾
Agents swept 230 channels and ingested 1,223 articles, then de-duplicated and ranked them for signal.
02Verified & cross-validated11 claims · 12 data feeds▾
Every one of 11 load-bearing claims was checked against primary sources, with 12 live data feeds reconciling the figures and charts.
- 1StockTitan, Form 144 notice, Erica Schwartz, Butterfly Network, 23 September 2026
- 2StockTitan, Form 144 notice, Joseph DeVivo, Butterfly Network, 22 September 2026
- 3Benzinga, Butterfly Stock Retreats: What's Going On Today?, 23 September 2026
- 4Business Wire via Morningstar, Butterfly Network Congratulates Dr. Erica Schwartz on Confirmation as CDC Director, 11 August 2026
- 5BioPharma Dive via Yahoo News, Erica Schwartz confirmed as next CDC director, 6 August 2026
- 6SEC EDGAR, Butterfly Network Form 4, Joseph DeVivo, gift of 250,000 shares, filed 25 August 2026
- 7SEC EDGAR, Butterfly Network Form 4, Joseph DeVivo, sale of 211,798 shares, filed 21 July 2026
- 8SEC EDGAR, Butterfly Network Form 4, Joseph DeVivo, sale of 68,346 shares, filed 12 August 2026
- 9SEC EDGAR, Butterfly Network Form 4, Erica Schwartz, director RSU grant showing 401,699 shares held, filed 22 June 2026
- 10NAI 500, BFLY Pops on Buy Call, Hedge Funds Pile In, 24 September 2026
- 11Sharadar quarterly fundamentals for Butterfly Network, from SEC filings, retrieved 24 September 2026
03Reviewed & edited1 human editor▾
One editor read the draft against the evidence, tuned the framing, and signed off before it shipped.
Become a contributor
Reporting on the business of AI and want it read? We take pitches from outside contributors who bring primary sources and a number worth arguing about.
Deepdive
AI-generated from this story and its cited sources. Not investment advice.



